Just as Novartis AG ‘s best-selling medicines are losing patent protection, the company is poised to get a revenue boost from a U.S. program designed to speed life- saving therapies to patients with few treatment options.

See the rest here: Novartis Boost Seen in Fast Cancer Drug Review as Protection Ends: Health

Shares of Aveo Pharmaceuticals plunged almost 50 percent Thursday after the company said a Food and Drug Administration panel recommended its drug Tivopath not be approved as a treatment for advanced kidney cancer.

Link: Aveo plunges as FDA recommends against cancer drug Shares of Aveo…

Shares of Aveo Pharmaceuticals Inc. plummeted more than 30 percent Tuesday after the Food and Drug Administration said another clinical trial may be needed to weigh the risks and benefits of the Cambridge company’s kidney cancer treatment.

Read the original: Shares of Aveo Pharmaceuticals plummet as FDA weighs new clinical trial for kidney cancer drug

Link: Fight to patent human genes goes to Supreme Court

Read this article: Positive Clinical Data Presented For Lead Accurin Candidate BIND-014 In Cancer Patients

NewLink Genetics Corporation , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO -dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer .

Go here to see the original: NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Swiss drugmaker Novartis had argued that it needed a new patent to protect its investment in the cancer drug Glivec, while activists said the company was trying to use loopholes to make more money out of a drug whose patent had expired.

Link: India ruling hailed as ‘good day’ for cancer patients

With 2012 revenues totaling $28.3 million, the focus of the company, which has 101 employees, is the research and development of detection and treatment technology for some of the most common cancers in the world.

Original post: Nashua-based iCAD gets Fda Ok for new cancer treatment

Mar 21, 2013 – Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the peer-reviewed publication of results from two Phase 3 clinical trials of Lymphoseek Injection in patients with breast cancer.

More here: Results of Lymphoseek Phase 3 Clinical Trials in Breast Cancer…

Roche said on Tuesday it clinched European approval for its breast cancer drug Perjeta, fuelling the company’s hopes that the drug will become the standard of care for an aggressive, incurable form of cancer.

See original here: Roche clinches EU approval for breast cancer drug Perjeta